Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Filings indexed 719 across all filing types
Latest filing 2023-06-16 Director's Dealing
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-06-16 English
FORM 4 SUBMISSION
Director's Dealing
2023-06-16 English
FORM 4/A SUBMISSION
Director's Dealing
2023-06-16 English
4
Director's Dealing
2023-06-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates that shareholders should know about. The text includes updates on cash position, clinical study results, and a press release and slide presentation attached as exhibits. It does not contain full financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It also is not a transcript, audit report, or other specialized filing. The document is primarily an operational and financial condition update and a press release with corporate presentation slides. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous filings like Form 8-K that do not fit other categories. The document length (8638 characters) and content confirm it is a full Form 8-K filing, not just a brief announcement or certification.
2023-06-05 English
4
Director's Dealing
2023-05-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.